Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
13.11B
Market cap13.11B
Price-Earnings ratio
27.99
Price-Earnings ratio27.99
Dividend yield
Dividend yield
Average volume
956.79K
Average volume956.79K
High today
$131.05
High today$131.05
Low today
$129.01
Low today$129.01
Open price
$130.43
Open price$130.43
Volume
358.53K
Volume358.53K
52 Week high
$160.18
52 Week high$160.18
52 Week low
$84.23
52 Week low$84.23

Stock Snapshot

The current Neurocrine(NBIX) stock price is $130.63, with a market capitalization of 13.11B. The stock trades at a price-to-earnings (P/E) ratio of 27.99.

On 2026-03-18, Neurocrine(NBIX) stock traded between a low of $129.01 and a high of $131.05. Shares are currently priced at $130.63, which is +1.3% above the low and -0.3% below the high.

The Neurocrine(NBIX)'s current trading volume is 358.53K, compared to an average daily volume of 956.79K.

During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.

During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $160.18 at its peak.

NBIX News

TipRanks 23h
Neurocrine appoints Andrew Ratz as Chief Technical Operations Officer

Neurocrine (NBIX) Biosciences announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his...

Simply Wall St 4d
Assessing Neurocrine Biosciences Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza

Neurocrine Biosciences (NBIX) has returned to investor attention after being identified as a leading Growth at a Reasonable Price candidate, together with a rea...

Assessing Neurocrine Biosciences Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza
TipRanks 6d
Neurocrine price target raised to $177 from $176 at JPMorgan

JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $177 from $176 and keeps an Overweight rating on the shares. The firm increased Crenessity estim...

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
16.1%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.